Meta-analysis finds asciminib improves major molecular response in chronic myeloid leukemia, reducing adverse events compared to tyrosine kinase inhibitors.
Key Points
Asciminib significantly improved major molecular response rates in chronic myeloid leukemia patients during follow-up.
The meta-analysis showed a decreased risk of grade ≥3 adverse events associated with asciminib compared to second-generation tyrosine kinase inhibitors.
RCTs reported 701 patients with a follow-up duration of 24–96 weeks assessing asciminib's efficacy.
These findings highlight the favorable safety profile of asciminib in chronic myeloid leukemia therapy.